What value do JAK inhibitors have in treating rheumatoid arthritis?

被引：3
作者：
Richez, Christophe [1 ,2 ]
Truchetet, Marie-Elise [1 ,2 ]
机构：
[1] CHU Bordeaux, Hop Pellegrin, Dept Rhumatol, Pl Amelie Raba Leon, F-33076 Bordeaux, France
[2] Univ Bordeaux, ImmunoConcept, CNRS, UMR 5164, Bordeaux, France
来源：
EXPERT OPINION ON PHARMACOTHERAPY | 2020年 / 21卷 / 15期
关键词：
Rheumatoid arthritis; targeted DMARDs; JAK; monotherapy; herpes zoster; thromboembolism; TOFACITINIB; METHOTREXATE; MONOTHERAPY; BARICITINIB; COMBINATION; ADALIMUMAB; PHASE-3; PLACEBO;
D O I：
10.1080/14656566.2020.1779703
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：1789 / 1792
页数：4
相关论文
共 25 条
[1]   A Case Series on Patients on Tofacitinib in Combination With a Biologic [J].
Barroso, Nashla S. ;
Miller, Elizabeth Z. ;
Furst, Daniel E. .
JCR-JOURNAL OF CLINICAL RHEUMATOLOGY, 2018, 24 (06) :349-351
[2]   Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial [J].
Burmester, Gerd R. ;
Blanco, Ricardo ;
Charles-Schoeman, Christina ;
Wollenhaupt, Juergen ;
Zerbini, Cristiano ;
Benda, Birgitta ;
Gruben, David ;
Wallenstein, Gene ;
Krishnaswami, Sriram ;
Zwillich, Samuel H. ;
Koncz, Tamas ;
Soma, Koshika ;
Bradley, John ;
Mebus, Charles .
LANCET, 2013, 381 (9865) :451-460
[3]   Risk Factors for Major Adverse Cardiovascular Events in Phase III and Long-Term Extension Studies of Tofacitinib in Patients With Rheumatoid Arthritis [J].
Charles-Schoeman, Christina ;
DeMasi, Ryan ;
Valdez, Hernan ;
Soma, Koshika ;
Hwang, Lie-Ju ;
Boy, Mary G. ;
Biswas, Pinaki ;
McInnes, Iain B. .
ARTHRITIS & RHEUMATOLOGY, 2019, 71 (09) :1450-1459
[4]   Rare diseases that mimic Systemic Lupus Erythematosus (Lupus mimickers) [J].
Chasset, Francois ;
Richez, Christophe ;
Martin, Thierry ;
Belot, Alexandre ;
Korganow, Anne-Sophie ;
Arnaud, Laurent .
JOINT BONE SPINE, 2019, 86 (02) :165-171
[5]  
COMBE B, 2019, ARTHRITIS RHEUMA S10, V71
[6]   Immunopathogenesis of Rheumatoid Arthritis [J].
Firestein, Gary S. ;
McInnes, Iain B. .
IMMUNITY, 2017, 46 (02) :183-196
[7]   Upadacitinib Versus Placebo or Adalimumab in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate: Results of a Phase III, Double-Blind, Randomized Controlled Trial [J].
Fleischmann, Roy ;
Pangan, Aileen L. ;
Song, In-Ho ;
Mysler, Eduardo ;
Bessette, Louis ;
Peterfy, Charles ;
Durez, Patrick ;
Ostor, AndrewJ ;
Li, Yihan ;
Zhou, Yijie ;
Othman, Ahmed A. ;
Genovese, Mark C. .
ARTHRITIS & RHEUMATOLOGY, 2019, 71 (11) :1788-1800
[8]   Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b/4, double-blind, head-to-head, randomised controlled trial [J].
Fleischmann, Roy ;
Mysler, Eduardo ;
Hall, Stephen ;
Kivitz, Alan J. ;
Moots, Robert J. ;
Luo, Zhen ;
DeMasi, Ryan ;
Soma, Koshika ;
Zhang, Richard ;
Takiya, Liza ;
Tatulych, Svitlana ;
Mojcik, Christopher ;
Krishnaswami, Sriram ;
Menon, Sujatha ;
Smolen, Josef S. .
LANCET, 2017, 390 (10093) :457-468
[9]   Safety and effectiveness of upadacitinib or adalimumab plus methotrexate in patients with rheumatoid arthritis over 48 weeks with switch to alternate therapy in patients with insufficient response [J].
Fleischmann, Roy M. ;
Genovese, Mark C. ;
Enejosa, Jeffrey V. ;
Mysler, Eduardo ;
Bessette, Louis ;
Peterfy, Charles ;
Durez, Patrick ;
Ostor, Andrew ;
Li, Yihan ;
Song, In-Ho .
ANNALS OF THE RHEUMATIC DISEASES, 2019, 78 (11) :1454-1462
[10]   Effect of Filgotinib vs Placebo on Clinical Response in Patients With Moderate to Severe Rheumatoid Arthritis Refractory to Disease-Modifying Antirheumatic Drug Therapy: The FINCH 2 Randomized Clinical Trial [J].
Genovese, Mark C. ;
Kalunian, Kenneth ;
Gottenberg, Jacques-Eric ;
Mozaffarian, Neelufar ;
Bartok, Beatrix ;
Matzkies, Franziska ;
Gao, Jie ;
Guo, Ying ;
Tasset, Chantal ;
Sundy, John S. ;
de Vlam, Kurt ;
Walker, David ;
Takeuchi, Tsutomu .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2019, 322 (04) :315-325
123